ICU Medical (NASDAQ:ICUI) Trading Up 10.2%

Shares of ICU Medical, Inc. (NASDAQ:ICUIGet Free Report) traded up 10.2% during mid-day trading on Tuesday . The stock traded as high as $95.97 and last traded at $95.75. 158,014 shares were traded during mid-day trading, a decline of 36% from the average session volume of 246,068 shares. The stock had previously closed at $86.88.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. TheStreet downgraded shares of ICU Medical from a “c-” rating to a “d+” rating in a research note on Tuesday, October 10th. KeyCorp began coverage on ICU Medical in a research note on Tuesday. They issued an “overweight” rating and a $134.00 target price on the stock. Finally, CL King initiated coverage on ICU Medical in a research note on Thursday, December 14th. They set a “buy” rating and a $110.00 price target for the company. One analyst has rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $122.00.

View Our Latest Research Report on ICUI

ICU Medical Stock Performance

The business has a 50 day moving average price of $94.26 and a two-hundred day moving average price of $113.21. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.99 and a current ratio of 2.63. The company has a market cap of $2.29 billion, a P/E ratio of -79.52 and a beta of 0.65.

ICU Medical (NASDAQ:ICUIGet Free Report) last released its quarterly earnings data on Monday, November 6th. The medical instruments supplier reported $1.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.94 by $0.29. The firm had revenue of $553.31 million for the quarter, compared to analysts’ expectations of $554.00 million. ICU Medical had a negative net margin of 1.25% and a positive return on equity of 6.53%. On average, sell-side analysts anticipate that ICU Medical, Inc. will post 5.07 earnings per share for the current year.

Insider Buying and Selling

In related news, VP Daniel Woolson sold 1,729 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $88.03, for a total value of $152,203.87. Following the completion of the sale, the vice president now owns 9,877 shares of the company’s stock, valued at $869,472.31. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.50% of the stock is owned by insiders.

Institutional Investors Weigh In On ICU Medical

Several hedge funds have recently made changes to their positions in the company. Raymond James & Associates increased its stake in ICU Medical by 42.5% during the 3rd quarter. Raymond James & Associates now owns 37,720 shares of the medical instruments supplier’s stock valued at $4,489,000 after purchasing an additional 11,256 shares in the last quarter. Daiwa Securities Group Inc. lifted its stake in shares of ICU Medical by 8.4% during the 2nd quarter. Daiwa Securities Group Inc. now owns 31,726 shares of the medical instruments supplier’s stock valued at $5,653,000 after buying an additional 2,466 shares in the last quarter. Swiss National Bank raised its holdings in ICU Medical by 1.1% during the second quarter. Swiss National Bank now owns 44,519 shares of the medical instruments supplier’s stock valued at $7,933,000 after acquiring an additional 500 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in ICU Medical by 10.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,001 shares of the medical instruments supplier’s stock worth $595,000 after purchasing an additional 455 shares in the last quarter. Finally, Knights of Columbus Asset Advisors LLC grew its holdings in ICU Medical by 16.7% during the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 1,848 shares of the medical instruments supplier’s stock valued at $220,000 after buying an additional 264 shares in the last quarter. 91.49% of the stock is currently owned by institutional investors.

About ICU Medical

(Get Free Report)

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; and ClearGuard HD, that maintains hemodialysis catheters.

Featured Articles

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.